Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases

Research output: Contribution to journalArticle

Abstract

EpCAM (CD326) has diverse roles in cell adhesion and proliferation, and is known to be overexpressed in primary breast carcinomas (PBCs). While clinical and preclinical data suggest a role for EpCAM in metastases, the only prior study of EpCAM expression in breast cancer metastases suggested that EpCAM expression is decreased after first-line chemotherapy. This study evaluates EpCAM expression in metastatic breast carcinoma (MBC) versus matched PBC . Rapid autopsies were performed on 17 patients with widely metastatic breast cancer. Single patient tissue microarrays (TMAs) were constructed from archived PBC and post-mortem MBCs. In total, 169 spots from 17 PBCs and 895 spots from 195 MBCs were labeled for EpCAM by immunohistochemistry (IHC). Expression was scored as intensity (1-3) multiplied by percent membrane labeling (0-100%) and was subclassified as low (0-100), moderate (101-200), or high (201-300) labeling. PBCs exhibited exclusively low-moderate EpCAM labeling. EpCAM labeling was present in all metastases and was significantly increased in MBCs of 14 of 17 patients (P value range

Original languageEnglish (US)
Pages (from-to)701-708
Number of pages8
JournalBreast Cancer Research and Treatment
Volume123
Issue number3
DOIs
StatePublished - Oct 2010

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Epithelial Cell Adhesion Molecule
Cell Adhesion
Autopsy
Immunohistochemistry
Cell Proliferation
Drug Therapy
Membranes

Keywords

  • Breast
  • Carcinoma
  • EpCAM
  • Metastasis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{9ee4dd6f132b424e8b845d4bf7944aac,
title = "Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases",
abstract = "EpCAM (CD326) has diverse roles in cell adhesion and proliferation, and is known to be overexpressed in primary breast carcinomas (PBCs). While clinical and preclinical data suggest a role for EpCAM in metastases, the only prior study of EpCAM expression in breast cancer metastases suggested that EpCAM expression is decreased after first-line chemotherapy. This study evaluates EpCAM expression in metastatic breast carcinoma (MBC) versus matched PBC . Rapid autopsies were performed on 17 patients with widely metastatic breast cancer. Single patient tissue microarrays (TMAs) were constructed from archived PBC and post-mortem MBCs. In total, 169 spots from 17 PBCs and 895 spots from 195 MBCs were labeled for EpCAM by immunohistochemistry (IHC). Expression was scored as intensity (1-3) multiplied by percent membrane labeling (0-100{\%}) and was subclassified as low (0-100), moderate (101-200), or high (201-300) labeling. PBCs exhibited exclusively low-moderate EpCAM labeling. EpCAM labeling was present in all metastases and was significantly increased in MBCs of 14 of 17 patients (P value range",
keywords = "Breast, Carcinoma, EpCAM, Metastasis",
author = "Cimino-Mathews, {Ashley M} and Halushka, {Marc K} and Illei, {Peter B} and Xinyan Wu and Saraswati Sukumar and Pedram Argani",
year = "2010",
month = "10",
doi = "10.1007/s10549-009-0671-z",
language = "English (US)",
volume = "123",
pages = "701--708",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases

AU - Cimino-Mathews, Ashley M

AU - Halushka, Marc K

AU - Illei, Peter B

AU - Wu, Xinyan

AU - Sukumar, Saraswati

AU - Argani, Pedram

PY - 2010/10

Y1 - 2010/10

N2 - EpCAM (CD326) has diverse roles in cell adhesion and proliferation, and is known to be overexpressed in primary breast carcinomas (PBCs). While clinical and preclinical data suggest a role for EpCAM in metastases, the only prior study of EpCAM expression in breast cancer metastases suggested that EpCAM expression is decreased after first-line chemotherapy. This study evaluates EpCAM expression in metastatic breast carcinoma (MBC) versus matched PBC . Rapid autopsies were performed on 17 patients with widely metastatic breast cancer. Single patient tissue microarrays (TMAs) were constructed from archived PBC and post-mortem MBCs. In total, 169 spots from 17 PBCs and 895 spots from 195 MBCs were labeled for EpCAM by immunohistochemistry (IHC). Expression was scored as intensity (1-3) multiplied by percent membrane labeling (0-100%) and was subclassified as low (0-100), moderate (101-200), or high (201-300) labeling. PBCs exhibited exclusively low-moderate EpCAM labeling. EpCAM labeling was present in all metastases and was significantly increased in MBCs of 14 of 17 patients (P value range

AB - EpCAM (CD326) has diverse roles in cell adhesion and proliferation, and is known to be overexpressed in primary breast carcinomas (PBCs). While clinical and preclinical data suggest a role for EpCAM in metastases, the only prior study of EpCAM expression in breast cancer metastases suggested that EpCAM expression is decreased after first-line chemotherapy. This study evaluates EpCAM expression in metastatic breast carcinoma (MBC) versus matched PBC . Rapid autopsies were performed on 17 patients with widely metastatic breast cancer. Single patient tissue microarrays (TMAs) were constructed from archived PBC and post-mortem MBCs. In total, 169 spots from 17 PBCs and 895 spots from 195 MBCs were labeled for EpCAM by immunohistochemistry (IHC). Expression was scored as intensity (1-3) multiplied by percent membrane labeling (0-100%) and was subclassified as low (0-100), moderate (101-200), or high (201-300) labeling. PBCs exhibited exclusively low-moderate EpCAM labeling. EpCAM labeling was present in all metastases and was significantly increased in MBCs of 14 of 17 patients (P value range

KW - Breast

KW - Carcinoma

KW - EpCAM

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=78649772250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649772250&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0671-z

DO - 10.1007/s10549-009-0671-z

M3 - Article

VL - 123

SP - 701

EP - 708

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -